Enanta 2025 Q4 Earnings 35.1% Net Loss Reduction to $18.7M

Enanta (ENTA) reported fiscal 2025 Q4 earnings on Nov 19, 2025. The company narrowed its net loss by 35.1% year-over-year and exceeded analyst expectations for EPS, despite missing revenue forecasts. Management reaffirmed its cash runway into fiscal 2029, signaling confidence in operational sustainability.

Revenue

The total revenue of Enanta increased by 3.5% to $15.13 million in 2025 Q4, up from $14.61 million in 2024 Q4.

Earnings/Net Income

Enanta narrowed losses to $0.87 per share in 2025 Q4 from a loss of $1.36 per share in 2024 Q4 (35.7% improvement). Meanwhile, the company successfully narrowed its net loss to $-18.70 million in 2025 Q4, reducing losses by 35.1% compared to the $-28.82 million net loss reported in 2024 Q4. The EPS improvement and net loss reduction reflect disciplined cost management and operational efficiency gains.

Price Action

The stock price of Enanta has edged down 1.14% during the latest trading day, has edged up 1.68% during the most recent full trading week, and has jumped 9.13% month-to-date.

Post-Earnings Price Action Review

Following the earnings report, Enanta’s stock experienced mixed short-term performance, with a 1.14% intraday decline but a 1.68% weekly recovery. The 9.13% monthly gain suggests growing investor confidence in the company’s long-term prospects, despite the revenue miss. Analysts attribute the positive momentum to improved profitability and a strengthened balance sheet.

CEO Commentary

President and CEO Jay R. Luly highlighted key drivers of the quarter, stating: “Our 3.5% revenue growth and 35.1% net loss reduction demonstrate our commitment to operational efficiency. Strategic investments in RSV and immunology pipelines, coupled with cost discipline, position us to advance transformative therapies while extending our cash runway into fiscal 2029. We remain focused on leveraging partnerships and capital-efficient development to deliver long-term value.”

Guidance

Enanta expects to maintain its current cash runway through fiscal 2029, supported by retained royalties and disciplined spending. The company also plans to submit an IND for EPS-3903 in H1 2026 and for EDP-978 in Q1 2026, aligning with its RSV and immunology development timelines.

Additional News

Recent non-earnings developments include JPMorgan initiating an Overweight rating with a $17 price target and Jefferies upgrading Enanta to Buy with a $20 target, citing RSV therapy potential. The company also completed a $74.75 million public offering in October 2025, bolstering its financial flexibility. Additionally, Enanta presented promising RSV drug data at IDWeek 2025, including zelicapavir’s efficacy in reducing symptom duration and EDP-323’s prophylactic potential.